Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated...
Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated...
Rigel Pharmaceuticals Highlights Initial Data From Ongoing Phase 1b Study Evaluating R289 In LR-MDS At The 66th ASH Annual Meeting; R289 Was Generally Well Tolerated And Demonstrated Signs Of Preliminary Clinical Activity In Elderly Heavily Pretreated LR-MDS Patients
rigel pharmaceuticals在第66届美国血液学会年会上重点介绍了正在进行的10亿阶段研究的初步数据，该研究评估了R289在LR-MDS中的应用；R289整体耐受性良好，并在重度预处理的老年LR-MDS患者中显示出初步临床活性的迹象。
- R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients
- RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD
- R289整体耐受性良好，并在重度预处理的老年LR-MDS患者中显示出初步临床活性的迹象。
- 在接受R289剂量≥500毫克QD的40%的可评估TD患者中发生了RBC-TI/HI-E反应。
SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS). The data is being presented today by Dr. Guillermo Garcia-Manero (Poster #: 4595) at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, in San Diego, California and virtually.
加利福尼亚州南旧金山，2024年12月9日 /芝加哥商业新闻/ -- rigel pharmaceuticals, Inc. (纳斯达克:RIGL)是一家专注于血液疾病和癌症的商业阶段生物技术公司，今天宣布了其正在进行的10亿阶段研究的初步数据，该研究评估了R2891——一种R835的口服前药，R835是一种有效且选择性强的双重抑制剂，对IRAK1和IRAK4在复发性或难治性(LR)低风险骨髓增生异常综合征患者中的应用。数据由Guillermo Garcia-Manero博士（海报编号：4595）在第66届美国血液学会(ASH)年会暨博览会期间于加利福尼亚州圣地亚哥和线上展示，会议时间为12月7日至10日。
